KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Amortization of Deferred Charges: 2011-2023

Historic Amortization of Deferred Charges for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Dec 2023 value amounting to $532,000.

  • Supernus Pharmaceuticals' Amortization of Deferred Charges rose 1.14% to $532,000 in Q1 2023 from the same period last year, while for Mar 2023 it was $2.1 million, marking a year-over-year decrease of 84.73%. This contributed to the annual value of $532,000 for FY2023, which is 74.81% down from last year.
  • According to the latest figures from FY2023, Supernus Pharmaceuticals' Amortization of Deferred Charges is $532,000, which was down 74.81% from $2.1 million recorded in FY2022.
  • Supernus Pharmaceuticals' 5-year Amortization of Deferred Charges high stood at $17.5 million for FY2021, and its period low was $532,000 during FY2023.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $2.1 million (2022), whereas its average is $6.7 million.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 32.58% in 2019, then crashed by 87.93% in 2022.
  • Over the past 5 years, Supernus Pharmaceuticals' Amortization of Deferred Charges (Yearly) stood at $15.7 million in 2019, then rose by 5.68% to $16.6 million in 2020, then grew by 5.43% to $17.5 million in 2021, then slumped by 87.93% to $2.1 million in 2022, then slumped by 74.81% to $532,000 in 2023.